- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT05227053
STOP AF Første eftergodkendelsesundersøgelse
STOP AF Første eftergodkendelsesundersøgelse, et tillæg til Cryo Global Registry
The STOP AF First PAS is a prospective, global, multi-center, observational trial.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
The STOP AF First Post Approval Study (PAS) is a sub-study to the Cryo Global Registry. The STOP AF First PAS is a prospective, global, multi-center, observational trial. The purpose of the study is to describe long-term clinical performance and safety data in the recurrent symptomatic paroxysmal AF population treated with Arctic Front™ and Freezor™ MAX Families of cardiac cryoablation catheters (hereafter referred to as Arctic Front™ Cardiac Cryoablation Catheter System) as an alternative to antiarrhythmic drug therapy as an initial rhythm control strategy. This PAS is a condition of the pre-market approval order (P100010/S110) by the U.S. Food and Drug Administration.
Undersøgelsestype
Tilmelding (Faktiske)
Kontakter og lokationer
Studiesteder
-
-
Alaska
-
Anchorage, Alaska, Forenede Stater, 99508
- Alaska Heart Institute
-
-
Connecticut
-
Stamford, Connecticut, Forenede Stater, 06905-5522
- Cardiology Associates of Fairfield County
-
-
District of Columbia
-
Washington D.C., District of Columbia, Forenede Stater, 20010
- MedStar Washington Hospital Center
-
-
Florida
-
Clearwater, Florida, Forenede Stater, 33756
- BayCare Medical Group Cardiology
-
Davie, Florida, Forenede Stater, 33328
- Heart Rhythm Solutions
-
-
Iowa
-
West Des Moines, Iowa, Forenede Stater, 50266
- Iowa Heart
-
-
Massachusetts
-
North Dartmouth, Massachusetts, Forenede Stater, 02747
- Southcoast Health System
-
-
Michigan
-
Detroit, Michigan, Forenede Stater, 48202-2608
- Henry Ford Heart & Vascular
-
-
Ohio
-
Cincinnati, Ohio, Forenede Stater, 45219
- The Lindner Research Center
-
-
Tennessee
-
Germantown, Tennessee, Forenede Stater, 38138
- Stern Cardiovascular Foundation
-
-
Texas
-
Dallas, Texas, Forenede Stater, 75231
- Texas Health Research and Education Institute
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Prøveudtagningsmetode
Studiebefolkning
Subjects ≥ 18 years of age (or minimum age as required by local regulations) who have a recommendation for a pulmonary vein ablation with the Arctic Front™ cardiac cryoablation catheter System.
Beskrivelse
Inclusion Criteria:
- Subject has been diagnosed with symptomatic paroxysmal AF
- Subject is ≥ 18 years of age or minimum age as required by local regulations
- Planned pulmonary vein isolation (PVI) procedure using the commercially available Arctic Front™ cardiac cryoablation catheter System.
- Willing to comply with study requirements and give informed consent (defined as legally effective, documented confirmation of a subject's voluntary agreement to participate in this clinical study) or authorization per institution and geographical requirements
Exclusion Criteria:
History of AF treatment with a class I or III antiarrhythmic drug, including sotalol, with the intention to prevent an AF recurrence1
. Subjects under the following conditions may be included in the study:
-
Temporary treatment with a class I or III AAD (treatment at a therapeutic dose for a period of <4 weeks prior to the index PVI procedure)
-
Recent treatment with a class I or III AAD (within 6 months of the index PVI procedure) at a dose below therapeutic threshold according to the AHA/ACC/HRS Guideline for the Management of Patients with Atrial Fibrillation
-
A subject who has received a chemical cardioversion may be included in the study. This includes a chemical cardioversion prior to enrollment and between enrollment and ablation.
- Subject has had a prior atrial ablation (except for cavo-tricuspid isthmus (CTI) ablation for AFL)
- Subject is enrolled in a concurrent study that has not been approved for concurrent enrollment by the global study manager
- Subject with exclusion criteria required by local law
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Observationsmodeller: COHORT
- Tidsperspektiver: PROSPECTIVE
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Freedom from Atrial Fibrillation (AF) /Atrial Flutter (AFL) /Atrial Tachycardia (AT)
Tidsramme: 36 months
|
Estimate the 36-month freedom from Atrial Fibrillation (AF) /atrial flutter (AFL) /Atrial Tachycardia (AT) recurrence using the Arctic Front™ cardiac cryoablation catheter System. |
36 months
|
|
Freedom from Primary Safety Events
Tidsramme: 12 months
|
Estimate primary safety Adverse Event (AE) rates for cryoablation using the Arctic Front™ cardiac cryoablation catheter System through 12-months. |
12 months
|
Samarbejdspartnere og efterforskere
Efterforskere
- Studieleder: Khaldoun Tarakji, MD, Medtronic CAS Chief Medical Officer
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- STOP AF First PAS
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .